Celcuity LLC
Yahoo Finance • yesterday
Why Celcuity Stock Popped Today
Key Points It very much surprised on the upside on the bottom-line result. It also has a much longer cash runway than it did at the end of 2024.10 stocks we like better than Celcuity › On Thursday, Celcuity(NASDAQ: CELC) issued its final... Full story
Yahoo Finance • yesterday
Stocks making the biggest moves midday: Meta, Best Buy, AppLovin, Scotts Miracle-Gro and more
Check out the companies making the biggest moves in midday trading: Meta Platforms — The social media giant tumbled more than 6%. Meta lost two major legal cases concerning child safety this week. While the financial penalties aren't large... Full story
Yahoo Finance • 2 days ago
Stocks making the biggest moves premarket: Micron, Sandisk, Newmont and more
Check out the companies making the biggest moves in premarket trading: Memory stocks — Shares of memory chipmakers tumbled following the unveiling of Google' s new AI model, which the company said could reduce the amount of memory required... Full story
Yahoo Finance • 2 days ago
Stocks making the biggest moves after hours: Worthington Steel, Karman, MillerKnoll and more
Check out the companies making headlines after the bell : MillerKnoll — The furniture stock plunged 14%. MillerKnoll posted fiscal third-quarter adjusted earnings of 43 cents on revenue of $926.6 million. That reflected a year-over-year de... Full story
Yahoo Finance • 22 days ago
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing
On February 17, 2026, Boxer Capital Management, LLC disclosed a buy of 135,000 shares of Celcuity(NASDAQ:CELC), an estimated $11.10 million trade based on quarterly average pricing. What Happened According to a February 17, 2026, SEC fil... Full story
Yahoo Finance • 22 days ago
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing
On February 17, 2026, Boxer Capital Management, LLC disclosed a new position in Terns Pharmaceuticals(NASDAQ:TERN), acquiring 375,000 shares in a transaction estimated at $15.15 million based on quarterly average pricing. What Happened B... Full story
Yahoo Finance • last month
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
On February 17, 2026, Perceptive Advisors disclosed a significant buy of 431,432 shares of Praxis Precision Medicines(NASDAQ:PRAX), with an estimated transaction value of $80.34 million based on quarterly average pricing, according to its... Full story
Yahoo Finance • last month
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
On February 17, 2026, Perceptive Advisors reported a buy of Celcuity(NASDAQ:CELC), adding 203,881 shares in the fourth quarter, with an estimated transaction value of $16.76 million based on quarterly average pricing. What happened Accor... Full story
Yahoo Finance • last month
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
On February 17, 2026, Perceptive Advisors disclosed a buy of 978,662 shares of Apogee Therapeutics(NASDAQ:APGE), with an estimated transaction value of $61.64 million based on quarterly average pricing. What happened According to a Febru... Full story
Yahoo Finance • last month
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
Perceptive Advisors disclosed a sale of 1,002,282 Arcellx(NASDAQ:ACLX) shares in a February 17, 2026, SEC filing, with the estimated transaction value at $79.96 million based on quarterly average pricing. What happened According to a SEC... Full story
Yahoo Finance • last month
Soleus Adds a Significant Number of Celcuity Shares
Key Points Soleus increased its Celcuity stake by 629,398 shares. The firm held over 1.8 million shares at the end of the quarter. Celcuity now accounts for 6.7% of fund AUM10 stocks we like better than Celcuity › On Feb. 12, Soleus Capi... Full story
Yahoo Finance • 2 months ago
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump
Key Points David Dalvey sold 20,000 shares indirectly on Jan. 27, 2026 for a transaction value of ~$2.4 million, at a weighted average price of $120.03 per share. The transaction represented 18.18% of Dalvey’s total indirect holdings prio... Full story
Yahoo Finance • 2 months ago
Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances
Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 investor letter. A copy of the letter can be downloaded here. Apis Flagship Fund delivered strong performance in the fourth quarter of 2025, with the Fund up 10.0% net for the... Full story
Yahoo Finance • 4 months ago
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presen... Full story
Yahoo Finance • 4 months ago
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 8th Annual Evercore Hea... Full story
Yahoo Finance • 4 months ago
Block upgraded, Dell downgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI A... Full story
Yahoo Finance • 4 months ago
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug... Full story
Yahoo Finance • 4 months ago
Block upgraded, Dell downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Truist upgraded Block (XYZ) to Hold fr... Full story
Yahoo Finance • 4 months ago
Celcuity outlines $2.5B–$3B peak revenue potential for gedatolisib amid accelerated launch preparations
Earnings Call Insights: Celcuity (CELC) Q3 2025 MANAGEMENT VIEW * CEO Brian Sullivan highlighted significant clinical and regulatory milestones, stating, "We made significant progress achieving a number of clinical and regulatory miles... Full story
Yahoo Finance • 4 months ago
Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Presented detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for Medical Oncology (“ESMO”) Congress Prese... Full story
